Phase 3 of LAG-3 antibody reached the primary endpoint!

LAG-3 is called lymphocyte activation gene-3, which is an immune checkpoint protein expressed on the surface of effector T cells and regulatory T cells (Tregs).

At present, LAG-3 has become one of the popular targets in the field of cancer immunotherapy, and many Chinese companies are also developing anti-LAG-3 antibodies.

1.

Target: LAG-3

IBI110 is a new type of anti-LAG-3 antibody developed by Cinda, which has been clinically approved in China and is intended to be developed for the treatment of blood cancers and solid tumors.

2.

Target: LAG-3 and PD-L1

IBI323 is a bispecific antibody developed by Innovent that can target LAG-3 and PD-L1 at the same time.

3.

Target: PD-1 and LAG-3

MGD013 is a bispecific antibody developed by MacroGenics that can simultaneously bind to PD-1 and LAG-3.

According to reports, MGD013 has a long half-life in serum and can simultaneously block the immunosuppression of the two immune checkpoint molecules PD-1 and LAG-3, and has the potential to treat a variety of solid tumors and malignant hematological cancers.

4.

Target: LAG-3

LBL-007 is a fully human monoclonal antibody of IgG4 subtype developed by Wei Lizhibo.

According to the information from the Chinese drug clinical trial registration and information disclosure platform, Wei Li Zhibo is carrying out two phase 1 clinical trials: one is designed to evaluate LBL-007 combined with PD-1 inhibitor teriprizumab in the first-line treatment of unresectable or metastatic treatment The safety, tolerability, and effectiveness of melanoma; the other is to evaluate the safety, tolerability, pharmacokinetics and effectiveness of LBL-007 in patients with advanced solid tumors and advanced lymphoma.

5.

Target: LAG-3

DNV3 is an anti-LAG-3 monoclonal antibody developed by Shimai Pharmaceutical.

In August 2020, DNV3 was granted a clinical implied license in China, and it is planned to be developed for the treatment of advanced/metastatic solid tumors and lymphomas.

6.
Anmai Bio: EMB-02

Target: PD-1 and LAG-3

EMB-02 is a bispecific antibody developed by Anmai Biotechnology that can simultaneously target the immune checkpoint proteins PD-1 and LAG-3.
In a preclinical model that is resistant to PD-1 antibody monotherapy, EMB-02 has shown significant anti-tumor activity.
Studies have shown that after treatment, half of the tumors in the EMB-02 administration group have completely regressed, while the PD-1 monoclonal antibody has no obvious anti-tumor effect in this model.
The drug has been approved by the US FDA for clinical entry in 2020.

In addition to the above-mentioned drugs, there are some antibodies targeting LAG-3 that are being developed.
Due to space limitations, this article will not introduce them one by one.
We look forward to more breakthroughs in the study of antibodies against LAG-3 and bring new treatment options to patients as soon as possible.